Physician profile
Gloria Rouhani
NPI 1912021643
$1,142.35
in general payments reported to CMS, 2019-2025
26 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $170 · 2021: $146 · 2022: $218 · 2023: $17.19 · 2024: $57.98 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $134.61 | 2019-2021 | |
| Therapeuticsmd, INC. | $102.00 | 2019-2021 | |
| Intuitive Surgical, INC. | $99.25 | 2022 | |
| Exeltis, USA INC. | $82.60 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $75.77 | 2025 | Novasure, Fluent Fluid Management System, Myosure Tissue Removal Device |
| Vertical Pharmaceuticals, LLC | $63.13 | 2019 | |
| Myovant Sciences INC. | $62.53 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $57.28 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $51.73 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $47.18 | 2019-2020 | |
| Sage Therapeutics, LLC | $43.78 | 2025 | Zurzuvae |
| Novo Nordisk INC | $33.87 | 2019 | |
| Covidien LP | $33.26 | 2020 | |
| Scynexis, INC. | $31.54 | 2022 | |
| Mayne Pharma Commercial LLC | $30.86 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.81 | 2019-2020 | |
| Dexcom, INC. | $24.17 | 2024 | Dexcom G6 Transmitter |
| Heron Therapeutics, INC. | $22.73 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.72 | 2025 | Qelbree |
| Pfizer INC. | $19.01 | 2025 | |
| Coopersurgical, INC. | $15.79 | 2022 | |
| Organon LLC | $15.21 | 2025 | Nexplanon |
| Allergan, INC. | $13.18 | 2019 | |
| Gilead Sciences, INC. | $12.99 | 2019 | |
| Ethicon US, LLC | $12.20 | 2021 | |
| Millicent US INC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Rouhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.